目的 探討八寶丹膠囊聯(lián)合哌拉西林他唑巴坦治療急性膽囊炎的臨床研究。方法 選取2021年1月—2021年12月南開(kāi)大學(xué)附屬醫(yī)院（天津市第四醫(yī)院）外科治療的80例急性膽囊炎患者，使用隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各40例。對(duì)照組靜脈滴注注射用哌拉西林鈉他唑巴坦鈉，2.25 g/次，加入0.9%氯化鈉250 mL中稀釋后靜脈滴注，2次/d。治療組在對(duì)照組的基礎(chǔ)上口服八寶丹膠囊，0.6 g/次，2次/d。兩組用藥7 d。觀察兩組的臨床療效，比較兩組癥狀好轉(zhuǎn)時(shí)間、血常規(guī)指標(biāo)、肝功能指標(biāo)和血清學(xué)因子水平。結(jié)果 治療后，治療組總有效率是97.50%，顯著高于對(duì)照組的77.50%（P＜0.05）。經(jīng)治療，治療組出現(xiàn)發(fā)熱、惡心嘔吐、右上腹壓痛、口苦等癥狀好轉(zhuǎn)時(shí)間均短于對(duì)照組（P＜0.05）。治療后，兩組白細(xì)胞（WBC）、中性粒細(xì)胞（NEUT）、天門(mén)冬酸氨基轉(zhuǎn)移酶（AST）、丙氨酸氨基轉(zhuǎn)移酶（ALT）均較治療前顯著降低（P＜0.05），治療后，治療組患者血常規(guī)及肝功能指標(biāo)改善優(yōu)于對(duì)照組（P＜0.05）。治療后，兩組患者白細(xì)胞介素-6（IL-6）、血清總膽汁酸（TBA）、腫瘤壞死因子-α（TNF-α）、C反應(yīng)蛋白（CRP）水平均較治療前顯著降低（P＜0.05），治療后，治療組血清學(xué)指標(biāo)水平低于對(duì)照組（P＜0.05）。結(jié)論 八寶丹膠囊聯(lián)合哌拉西林他唑巴坦治療療效確切，能使癥狀顯著改善，對(duì)肝臟損傷程度減輕，能降低體內(nèi)炎癥反應(yīng)，且藥物安全有效，值得臨床推廣。

Objective To investigate the clinical effect of Babaodan Capsules combined with piperacillin sodium and tazobactam sodium in treatment of acute cholecystitis. Methods A total of 80 patients with acute cholecystitis who received surgical treatment in Affiliated Hospital of Nankai University (Tianjin Fourth Hospital) from January 2021 to December 2021 were selected. All patients were divided into control group and treatment group by random number table method, with 40 cases in each group. Patients in the control group were iv administered with Piperacillin Sodium and Tazobactam Sodium for injection, 2.25 g/time, diluted into 250 mL 0.9% sodium chloride, intravenous infusion, twice daily. Patients in the treatment group were po administered with Babaodan Capsules on the basis of the control group, 0.6 g/time, twice daily. Both groups took the medicine for 7 d. The clinical efficacy of the two groups were observed, and the symptom improvement time, blood routine indexes, liver function indexes, and serological factors levels of the two groups were compared. Results After treatment, the total effective rate of the treatment group was 97.50%, significantly higher than that of the control group (77.50%) (P < 0.05). After treatment, the improvement time of fever, nausea and vomiting, right upper abdominal tenderness, bitter mouth in the treatment group was shorter than that in the control group (P < 0.05). After treatment, the indexes of white blood cell (WBC), neutrophil (NEUT), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) in two groups were significantly decreased compared with those before treatment (P < 0.05). After treatment, the improvement of blood routine and liver function indexes in treatment group was better than that in control group (P < 0.05). After treatment, the levels of interleukin-6 (IL-6), serum total bile acid (TBA), tumor necrosis factor α (TNF-α), and C-reactive protein (CRP) in two groups were significantly decreased compared with those before treatment (P < 0.05). The serum indexes in treatment group were lower than those in control group (P < 0.05).Conclusion Babaodan Capsules combined with piperacillin sodium and tazobactam sodium has curative effect in treatment of acute cholecystitis, and can significantly improve the symptoms, reduce the degree of liver injury and the inflammatory response safely and effectively, which is worthy of clinical promotion.

R975